The stock of Trillium Therapeutics Inc (TSE:TR) is a huge mover today! About 53,435 shares traded hands or 735.05% up from the average. Trillium Therapeutics Inc (TSE:TR) has risen 58.48% since March 30, 2016 and is uptrending. It has outperformed by 57.26% the S&P500.
The move comes after 9 months negative chart setup for the $85.32 million company. It was reported on Nov, 3 by Barchart.com. We have $9.32 PT which if reached, will make TSE:TR worth $8.53 million less.
More recent Trillium Therapeutics Inc (TSE:TR) news were published by: Marketwatch.com which released: “Trillium Therapeutics Inc.” on August 24, 2009. Also Medgadget.com published the news titled: “Trillium Therapeutics Inc Clinical Trial Review, Market Size, Segment, and …” on November 01, 2016. Etfdailynews.com‘s news article titled: “Trillium Therapeutics Inc. (TRIL): Finding The Next Blockbuster Biotech Stock” with publication date: June 23, 2015 was also an interesting one.
Trillium Therapeutics Inc is a Canada clinical stage immuno-oncology firm developing therapies for the treatment of cancer. The company has a market cap of $85.32 million. The Company’s SIRPaFc program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It currently has negative earnings. It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.